Taverner S, Eng C, Watson R, George S, Edwards A, Williams DM, Stephens JW. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
Diabetes Metab Syndr 2022;
16:102658. [PMID:
36371968 DOI:
10.1016/j.dsx.2022.102658]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 08/11/2022] [Accepted: 10/26/2022] [Indexed: 11/06/2022]
Abstract
BACKGROUND AND AIMS
Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are associated with diabetic ketoacidosis (DKA), however limited case series are published.
METHODS
We evaluated the characteristics of patients admitted with SGLT-2i associated DKA.
RESULTS
Over 4 months, 22 patients were identified; 45.5% of DKA was not associated with concurrent illness.
CONCLUSION
DKA is not uncommonly associated with SGLT2i with no clear patient factors associated with severity.
Collapse